Although considered plasma prognostic biomarkers, the MMP-2 and MMP-8 pathways in the lung could become the target of specific therapies, including those proposed to diminish cell infiltration, viral immunosuppression response, oxidative stress, and tissue damage during COVID-19. The gene discussed is MMP2; the disease is COVID-19.